---
title: "Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293659753.md"
description: "Genmab clarified primary endpoints for the Phase 3 EPCORE DLBCL-1 trial of epcoritamab. In the U.S., overall survival was the sole primary endpoint, which the study missed with no statistically significant improvement. The trial uses region-specific endpoints, differing from earlier messaging, with additional results pending journal submission."
datetime: "2026-07-23T20:00:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293659753.md)
  - [en](https://longbridge.com/en/news/293659753.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293659753.md)
---

# Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial

-   Genmab issued a clarification correcting how primary endpoints were described for the Phase 3 EPCORE DLBCL-1 epcoritamab trial. \* In the U.S., overall survival was the sole primary endpoint; the study missed it, with no statistically significant overall survival improvement. \* The trial uses region-specific primary endpoints, creating a mismatch with earlier topline messaging; additional results are slated for journal submission. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 20260723712759) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [First Trust Advisors LP Purchases 1,126,069 Shares of Genmab A/S Sponsored ADR $GMAB](https://longbridge.com/en/news/293838796.md)
- [AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis](https://longbridge.com/en/news/294086753.md)
- [Hyperscalers can't win with investors as they spend big on AI](https://longbridge.com/en/news/293912231.md)
- [Genmab Announces Positive Phase 3 Results For Epcoritamab Plus Lenalidomide](https://longbridge.com/en/news/291234509.md)
- [AbbVie (NYSE:ABBV) Releases Q2 2026 Earnings Guidance](https://longbridge.com/en/news/291948764.md)